Who is sponsoring NCT05213286?

NCT05213286 is sponsored by Glostrup University Hospital, Copenhagen.

What drugs are being tested in NCT05213286?

Interventions in NCT05213286: Application of ZAQ and RAADS-R-DK.

What condition does NCT05213286 study?

NCT05213286 studies Autism Spectrum Disorder, Schizotypal Disorder.

Is NCT05213286 still recruiting?

NCT05213286 is currently status unknown. Last updated 16 March 2022.

Last reviewed 2022-03-16 · How we verify

NCT05213286: ZA-RAA

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Development of a Screening Questionnaire to Discriminate Autism Spectrum Disorder and Schizotypal Disorder, and Validation of the Danish Version of RAADS-R

Status unknown NA Last updated 16 March 2022

What this trial tests

NA trial testing Application of ZAQ and RAADS-R-DK in Autism Spectrum Disorder in 600 participants. Status unknown.

Timeline

1 February 2022

Primary endpoint
31 August 2023

31 August 2023

Quick facts

Lead sponsor	Glostrup University Hospital, Copenhagen
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	diagnostic
Enrollment	600
Start date	1 February 2022
Primary completion	31 August 2023
Estimated completion	31 August 2023
Sites	1 location across Denmark

Drugs / interventions tested

Application of ZAQ and RAADS-R-DK

Conditions studied

Autism Spectrum Disorder — all drugs for Autism Spectrum Disorder →
Schizotypal Disorder — all drugs for Schizotypal Disorder →

Sponsor

Glostrup University Hospital, Copenhagen

Who can join

Adults 18 to 65, any sex, with Autism Spectrum Disorder or Schizotypal Disorder. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of the study is to investigate the validity, reliability and clinical features of a Danish version of the Ritvo Autism Asperger Diagnostic Scale-Revised (RAADS-R). A self-reporting scale devise used as a supplementary questionnaire in diagnosing autism spectrum disorder (ASD) in adults. Furthermore the validity of novel screening questionnaire: SchiZotypal Autism Questionnaire (ZAQ), will be investigated. ZAQ is developed to discriminate Schizotypal Disorder from ASD.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Protocol for the development and testing of the schiZotypy Autism Questionnaire (ZAQ) in adults: a new screening tool to discriminate autism spectrum disorder from schizotypal disorder.
Parvaiz R, Vindbjerg E, Crespi B, Happe F, et al · · 2023 · cited 2× · PMID 36978026 · DOI 10.1186/s12888-023-04690-3
Validation of a screening tool for autism spectrum disorder in adults - a study protocol.
Parvaiz R, Al-Sayegh Z, Jacobsen PK, Danielsen IM, et al · · 2022 · PMID 36458608

Verify or expand the search:

Other recruiting trials for Autism Spectrum Disorder

Currently open trials in the same condition.

NCT07324057 — The Effects of Preoperative Intranasal Administration of Dexmedetomidine and Esketamine on Negative Postoperative Behavi · NA · recruiting
NCT07493096 — Intensive Multimodal Neurorehabilitation Targeting Neuroplasticity in Pediatric Neurodevelopmental and Chromosomal Disor · recruiting
NCT07505290 — Efficacy of the Korean PEERS® for Preschoolers (PEERS®-PS-K) Social Skills Intervention: A Randomized Controlled Trial f · NA · active not recruiting
NCT07524192 — A Self-Instructional Online Program for Early Childhood and Elementary Teachers Supporting Autistic Children and Childre · NA · recruiting
NCT07432776 — Effect of an 8-Week Pickleball Program for Adults With Autism: A Feasibility Trial With a Delayed-Control Design · EARLY_PHASE1 · recruiting

Other Glostrup University Hospital, Copenhagen trials

Trials by the same sponsor.

NCT07442773 — Intervention to Support Partners and Informal Caregivers of Frail RA-patients · NA · recruiting
NCT07318129 — Indole-3-PROpionic Acid Clinical Trials - Multiple Sclerosis · NA · recruiting
NCT07105514 — Indole-3-PROpionic Acid Clinical Trials - a Pilot Study Part 2 · NA · recruiting
NCT06533423 — Effect of a Self-Management Intervention for Patients Newly Diagnosed With Inflammatory Arthritis: The NISMA Trial · NA · recruiting
NCT06674018 — Indole-3-PROpionic Acid Clinical Trials - a Pilot Study · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05213286 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Glostrup University Hospital, Copenhagen
Last refreshed: 16 March 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05213286.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing